INJECTABL-II: Dose Finding, Efficacy and Immunological Response of a Novel Immuno-Adjuvant (IP-001) Following Radiofrequency Ablation, Microwave Ablation or Irreversible Electroporation for Colorectal Liver Metastases.
Latest Information Update: 14 Oct 2024
At a glance
- Drugs N-dihydro-galacto-chitosan (Primary)
- Indications Colorectal cancer; Liver metastases
- Focus Adverse reactions; Therapeutic Use
- Acronyms INJECTABL-II
- 14 Oct 2024 New trial record